Importance Luminal and basal subtypes of primary prostate cancer have been shown to be
molecularly distinct and clinically important in predicting response to therapy. These
subtypes have not been described in metastatic prostate cancer. Objectives To identify
clinical and molecular correlates of luminal and basal subtypes in metastatic castration-
resistant prostate cancer (mCRPC) and investigate differences in survival, particularly after
treatment with androgen-signaling inhibitors (ASIs). Design, Setting, and Participants In this …